U Gessner
Overview
Explore the profile of U Gessner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gobel H, Gessner U, Petersen-Braun M, Weingartner U
Schmerz
. 2006 Sep;
21(1):49-54, 56.
PMID: 16955294
Background: The aim of the study was to investigate the efficacy and tolerability of acetylsalicylic acid in the treatment of acute migraine attacks by self-medication under daily life conditions when...
2.
Schulz H, Schurer M, Krupp S, Dammann H, Timm J, Gessner U
Int J Clin Pharmacol Ther
. 2004 Oct;
42(9):481-7.
PMID: 15487806
Objective: This study investigated concentrations of ascorbic acid (ASC) in gastric mucosa, gastric juice, urine and plasma in healthy subjects under steady state and fasted conditions with and without concomitant...
3.
Diener H, Eikermann A, Gessner U, Gobel H, Haag G, Lange R, et al.
Eur Neurol
. 2004 Jul;
52(1):50-6.
PMID: 15240983
Recently a new effervescent acetylsalicylic acid (ASA) tablet with high buffering capacity has been developed. In this double-blind, 3-arm, multicenter, parallel-group study, 433 patients were treated either with 1,000 mg...
4.
Dammann H, Saleki M, Torz M, Schulz H, Krupp S, Schurer M, et al.
Aliment Pharmacol Ther
. 2004 Feb;
19(3):367-74.
PMID: 14984384
Background: The most frequently reported adverse events associated with acetylsalicylic acid intake are minor gastrointestinal complaints. Galenic modifications, such as buffered formulations with or without ascorbic acid, may improve the...
5.
Gessner U, Koeberle D, Thuerlimann B, Bacchus L, Horisberger B
Support Care Cancer
. 2000 Mar;
8(2):115-22.
PMID: 10739358
The goals of this study were the assessment (1) of all costs of terminal care of patients with osteolytic bone disease and pain and (2) of the economic consequences of...
6.
Sagmeister M, Gessner U, Horisberger B, Gutzwiller F
Schweiz Med Wochenschr
. 1998 Apr;
128(10):356-62.
PMID: 9556830
Mortality from ischemic heart disease (ICD 410-414) is changing. Remarkable decreases have been observed in the age groups from 35-64 years, while overall mortality (all age groups) has remained approximately...
7.
Sagmeister M, Gessner U, Oggier W, Horisberger B, Gutzwilller F
Eur Heart J
. 1997 Jul;
18(7):1102-9.
PMID: 9243143
Aims: Direct and indirect costs of ischaemic heart disease were assessed in Switzerland, for the period 1988-1993, in order to evaluate the economic consequences of more intensive treatment of the...
8.
Sagmeister M, Gessner U, Kind C, Horisberger B
Schweiz Med Wochenschr Suppl
. 1995 Jan;
65:103S-112S.
PMID: 7716447
A comprehensive cost-benefit analysis of possible screening strategies for congenital toxoplasmosis is necessary as a basis for the decision whether or not screening is efficient and socially desirable. The total...
9.
10.
Gessner U
J Clin Eng
. 1991 Jan;
16(1):61-4.
PMID: 10109832
The clinical engineering or medical engineering departments in the hospitals in Switzerland are in a phase of rapid development. In particular, staffing, as well as official recognition by hospital management,...